HSHarrison Specht

Harrison Specht

*This is an algorithmically generated author record based on publicly available information.

Harrison Specht has a total of 98 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    How to Design 1000-Plex Mass Tags Using the Differential Mass Defect

    by Harrison Specht, Kevin McDonnell, Daniel J. Geiszler, Michael P. Agius

    Multiplexing samples in mass-spectrometry-based proteomics has long been accomplished by isotopologues of small molecules. These chemically identical “mass tags” conjugate to peptides to encode samples with different mass offsets for parallel analysis. The current state of the art for multiplexing with nonisobaric mass tags was recently improved from 3-plex to 9-plex, but what is the largest plex size that can be reasonably achieved with current technology? A full answer to this question requires evaluating current mass spectrometry hardware, facets of which have been well investigated by others. However, it may be underappreciated that multiplexing 1000s of samples with mass tags does not actually require 1000s of isotopes or 1000s of synthesis steps to create. Nonintuitively, high-plex mass tags can require relatively few different isotopes. The focus of this exposition is to characterize the potential of the differential mass defect to create tens to over a thousand isotopologues of small molecules and how careful combinations of these small molecules can combinatorially scale the plex size to minimize the number of synthetic steps. Importantly, we show using formulas from publicly reported compounds that plex sizes in the hundreds, an order of magnitude greater than the state of the art, are achievable using molecules comparable in size to existing commercial tags and that going beyond hundreds may require larger molecules. Additionally, we show how plexing with the differential mass defect allows significantly higher-purity yields during reagent creation for a given plex size. In summary, we investigated and present here how the differential mass defect must be utilized to create high-plex mass tags with limited dopable sites.

  • Open Access

    How to design 1000-plex mass tags using the differential mass defect

    by Harrison Specht, Michael P. Agius, Kevin McDonnell

    Multiplexing samples in mass spectrometry-based proteomics has long been accomplished by iso-topologues of small molecules. These chemically-identical “mass tags” conjugate to peptides to encode samples with different mass offsets for parallel analysis. The current state-of-the-art for multiplexing with non-isobaric mass tags was recently improved from 3-plex to 9-plex, but what is the largest plex size that can be reasonably achieved with current technology? A full answer to this question requires evaluating current mass spectrometry hardware, facets of which have been well-investigated by others. However, it may be underappreciated that multiplexing 1000s of samples with mass tags does not actually require 1000s of isotopes, or 1000s of synthesis steps to create. Non-intuitively, high plex mass tags can require relatively few different isotopes. The focus of this exposition is to characterize the potential of the differential mass defect to create tens to over a thousand isotopologues of small molecules and how careful combinations of these small molecules can combinatorially scale the plex size to minimize synthetic steps. Importantly, we show that plex sizes in the hundreds, an order of magnitude greater than state-of-the-art, are achievable using molecules comparable in size to existing commercial tags, and that going beyond hundreds may require larger molecules. Approaches to achieve high-plex proteomics will almost certainly require using the differential mass defect, so we hope this exposition serves to accelerate progress in reagent development to achieve high plex proteomics.


  • Open Access

    PSMtags improve peptide sequencing and throughput in sensitive proteomics

    by Harrison Specht, Maddy Yeh, Sarah Sipe, David Barnes-Seeman, Mark Adamo, Kevin McDonnell, Michael P. Agius, Corinna Friedrich, Wai Kit Pang, Yanchang Huang, et al.

    Mass spectrometry-based proteomics enables comprehensive characterization of proteins, but label-free approaches are challenging to scale to thousands of samples per day (SPD). Multiplexed data-independent approaches (plexDIA) can increase throughput but lack the mass tags to enable it. Here, we systematically screened a library of 576 compounds and identified several small molecules that, when conjugated to peptides, improve their detection and sequence identification. The lead molecule, PSMtag, substantially increases the detection of fragment b-ions, which increases the confidence of sequence identification and enhances de novo sequencing. PSMtags allow 9-plexDIA, using only stable isotopes of carbon, oxygen and nitrogen. As a result, it allows increasing sample throughput for plexDIA workflows. We demonstrate 1,130 SPD with 9-plexDIA from single-cell-level human proteomes, acquiring 27,520 protein datapoints in the same time label-free methods acquire 3,216. Our approach constitutes an expandable framework for developing mass tags to overcome existing limitations in multiplexed proteomics.


  • Open Access

    timePlex: Increasing mass spectrometry throughput using time-encoded sample multiplexing

    by Jason Derks, Kevin McDonnell, Nathan Wamsley, Peyton Stewart, Maddy Yeh, Harrison Specht, Nikolai Slavov

    Liquid chromatography-mass spectrometry (LC-MS) can enable precise and accurate quantification of analytes at high-sensitivity, but the rate at which samples can be analyzed remains limited. Throughput can be increased by data-independent-acquisition (DIA) using short separation times and by multiplexing samples in the mass domain with plexDIA; yet multiplexing along one dimension scales throughput only linearly with plex. To enable combinatorial scaling of proteomics throughput, we developed a complementary DIA strategy that multiplexes samples in the time domain, termed `timePlex'. timePlex staggers and overlaps the separation periods of individual samples. This strategy is orthogonal to isotopic multiplexing, which enables combinatorial multiplexing in mass and time domains, and thus multiplicatively increased throughput. We demonstrate this with a 27-plex (3-timePlex and 9-plexDIA) exceeding 1,200 samples (4M protein datapoints) per day. These results establish timePlex as a framework for multiplexing both label-free and labeled samples that supports sensitive and accurate protein quantification and combinatorial scaling.


  • Open Access

    JMod: Joint modeling of mass spectra for empowering multiplexed DIA proteomics

    by Kevin McDonnell, Daniel J. Geiszler, Nathan Wamsley, Jason Derks, Sarah Sipe, Zachary A. Cohen, Lina Kozhaya Warinner, Maddy Yeh, Eunice Koo, Andrew Leduc, et al.

    Parallelization of data acquisition substantially increases the throughput of mass spectrometry-based proteomics. However, parallelization also increases the density of mass spectra and consequently the overlap between ions, frustrating their analysis. To improve sequence identification and quantification from such spectra, we developed an open-source software for Joint Modeling of mass spectra (JMod). JMod models overlapping peaks as linear super-positions of their components in both MS1 and MS2 space, which permits multiplexed DIA with smaller mass offsets to increase the multiplexing capacity and thus proteomics through-put for a given plexDIA tag. This enables 9-plexDIA using 2 Da offset PSMtags, increasing throughput 9-fold while preserving quantitative accuracy and coverage depth. Furthermore, we use JMod to deconvolve simultaneous labeling by mass tags and heavy amino acids, thus increasing the throughput of metabolic pulse experiments measuring protein synthesis and degradation rates in single cells from mouse liver. By supporting enhanced decoding of highly multiplexed DIA spectra, JMod provides an open and flexible software that increases the throughput of sensitive proteomics.


  • Open Access

    BCG vaccination of Diversity Outbred mice induces cross-reactive antibodies to SARS-CoV-2 spike protein

    by Aubrey G. Specht, Sherry L. Kurtz, Karen L. Elkins, Harrison Specht, Gillian Beamer

    The Bacillus Calmette-Guérin (BCG) vaccine, the only vaccine against tuberculosis, induces cross-protection against pathogens unrelated to Mycobacterium , including viruses. Epidemiological studies have identified potential benefits of BCG vaccination against SARS-CoV-2 infection. While BCG’s heterologous effects have been widely attributable to trained immunity , we hypothesized BCG vaccination could induce cross-reactive antibodies against the spike protein of SARS-CoV-2 Wuhan-Hu-1. The concentration of IgG reactive to SARS-CoV-2 spike protein from the sera of BCG-vaccinated, Diversity Outbred (DO) mice and C57BL/6J inbred mice was measured using ELISA. Sera from 10/15 BCG-vaccinated DO mice possessed more IgG reactive to recombinant spike protein than sera from BCG-vaccinated C57BL/6J mice and unvaccinated DO mice. Amino acid sequences common to BCG cell wall/membrane proteins and SARS-CoV-2 spike protein were identified as potential antigen candidates for future study. These results imply a humoral mechanism, influenced by genotype, by which BCG vaccination could confer immunity to SARS-CoV-2. Graphic


  • Open Access

    Prioritized single-cell proteomics reveals molecular and functional polarization across primary macrophages

    by R Gray Huffman, Andrew Leduc, Christoph Wichmann, Marco di Gioia, Francesco Borriello, Harrison Specht, Jason Derks, Saad Khan, Luke Khoury, Edward Emmott, et al.

    Major aims of single-cell proteomics include increasing the consistency, sensitivity, and depth of protein quantification, especially for proteins and modifications of biological interest. To simultaneously advance all these aims, we developed prioritized Single Cell ProtEomics (pSCoPE). pSCoPE consistently analyzes thousands of prioritized peptides across all single cells (thus increasing data completeness) while analyzing identifiable peptides at full duty-cycle, thus increasing proteome depth. These strategies increased the sensitivity, data completeness, and proteome coverage over 2-fold. The gains enabled quantifying protein variation in untreated and lipopolysaccharide-treated primary macrophages. Within each condition, proteins covaried within functional sets, including phagosome maturation and proton transport. This protein covariation within a treatment condition was similar across the treatment conditions and coupled to phenotypic variability in endocytic activity. pSCoPE also enabled quantifying proteolytic products, suggesting a gradient of cathepsin activities within a treatment condition. pSCoPE is freely available and widely applicable, especially for analyzing proteins of interest without sacrificing proteome coverage. Support for pSCoPE is available at: scp.slavovlab.net/pSCoPE Abstract Figure:


  • Open Access

    TAILS Identifies Candidate Substrates and Biomarkers of ADAMTS7, a Therapeutic Protease Target in Coronary Artery Disease

    by Bryan T. MacDonald, Hasmik Keshishian, Charles C. Mundorff, Alessandro Arduini, Daniel Lai, Kayla Bendinelli, Nicholas R. Popp, Bidur Bhandary, Karl R. Clauser, Harrison Specht, et al.


  • Open Access

    Increasing the throughput of sensitive proteomics by plexDIA

    by Jason Derks, Andrew Leduc, Georg Wallmann, R. Gray Huffman, Matthew Willetts, Saad Khan, Harrison Specht, Markus Ralser, Vadim Demichev, Nikolai Slavov

    Current mass-spectrometry methods enable high-throughput proteomics of large sample amounts, but proteomics of low sample amounts remains limited in depth and throughput. To increase the throughput of sensitive proteomics, we developed an experimental and computational framework, plexDIA, for simultaneously multiplexing the analysis of both peptides and samples. Multiplexed analysis with plexDIA increases throughput multiplicatively with the number of labels without reducing proteome coverage or quantitative accuracy. By using 3-plex nonisobaric mass tags, plexDIA enables quantifying 3-fold more protein ratios among nanogram-level samples. Using 1 hour active gradients and first-generation Q Exactive, plexDIA quantified about 8,000 proteins in each sample of labeled 3-plex sets. plexDIA also increases data completeness, reducing missing data over 2-fold across samples. We applied plexDIA to quantify proteome dynamics during the cell division cycle in cells isolated based on their DNA content; plexDIA detected many classical cell cycle proteins and discovered new ones. When applied to single human cells, plexDIA quantified about 1,000 proteins per cell and achieved 98 % data completeness within a plexDIA set while using about 5 min of active chromatography per cell. These results establish a general framework for increasing the throughput of sensitive and quantitative protein analysis.